All In Biotech

Drug Trial Radar · NCT07299825

A Study of A166 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer

Phase 2 Study of A166 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With TOP1-ADCs

Last checked: Nov 19, 2026Latest source record: May 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Sep 20, 2024

Primary completion

Sep 20, 2027

Study completion Dec 31, 2027

Sponsor

Sponsor type
Industry
First posted
Dec 23, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Evaluation of the efficacy of A166 in Patients with HER2-Positive unresectable or metastatic breast cancer previously treated with TOP1 inhibitor Antibody-Drug Conjugates

Conditions

  • Her 2 Positive Breast Cancer

Interventions

  • A166Drug

    intravenous(IV) infusion (Q3W)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective response rate(ORR)Time frame: Within 24 months of last patient enrolled

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Henan Provincial Cancer Hospital

    Zhenzhou, Henan, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.